JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
PMID:37278811
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G; VX21-121-105 Study Group.
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.
Lopes-Pacheco M.
Front Pharmacol. 2020 Feb 21;10:1662. doi: 10.3389/fphar.2019.01662. eCollection 2019.
PMID:32153386
Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.
Wine E, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M, Gianolio L, Gordon H, Hojsak I, Hudson AS, Hussey S, van Limbergen J, Miele E, Norsa L, Olén O, Pellino G, van Rheenen P, de Ridder L, Russell RK, Shouval DS, Trindade E, Turner D, Wilson DC, Yerushalmy Feler A, Assa A.